Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Satellos Bioscience Inc > Desjardins 23,042,023 bought 23,322,376 sold
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by AcynicalJedion Jun 27, 2018 1:35pm
75 Views
Post# 28238128

RE:RE:RE:RE:RE:RE:RE:Desjardins 23,042,023 bought 23,322,376 sold

RE:RE:RE:RE:RE:RE:RE:Desjardins 23,042,023 bought 23,322,376 sold
tdub2013 wrote: Ahhh, I get it!  That makes sense :)
So when someone was mentioning about Desjardins doing all of these trades and manipulating the price .... that isn't actually the institution themselves, but some traders who use Desjardins are their discount brokerage house?
I appreciate the "tutoring" guys


Dont get me wrong,manipulation happens and the different houses do indeed buy and sell shares for themselves.

However those that insist that it is 1 guy at Desjardins doing all the buying and selling or Td or Jitney or whoever they want to name dont have a clue how things work.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities